Corsair Capital Management L.P. Acquires Shares of 10,000 Halozyme Therapeutics, Inc. $HALO

Corsair Capital Management L.P. bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $646,000.

Several other large investors also recently modified their holdings of the stock. Empowered Funds LLC bought a new stake in Halozyme Therapeutics during the first quarter worth about $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC increased its holdings in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Morgan Stanley cut their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,102 shares of company stock worth $5,205,798 in the last ninety days. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $81.93 on Monday. The stock has a 50-day moving average price of $73.08 and a two-hundred day moving average price of $70.58. Halozyme Therapeutics, Inc. has a 12 month low of $57.67 and a 12 month high of $82.99. The company has a market capitalization of $9.72 billion, a PE ratio of 29.47, a P/E/G ratio of 0.34 and a beta of 0.84. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the previous year, the business posted $1.11 earnings per share. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.